Avid Bioservices Inc (CDMO)

[The Other Guy]

From the 3/7/2014 Conference Call:

Steve King:

During the last quarterly call, I introduced Stephen Worsley as our VP of Business Dev. Steve has hit the ground running since joining us, and along with his business development reports, have been active on all fronts. While specifics cannot be discussed until deals are culminated, what I can say is that we have seen a high level of interest from potential partners in the bavituximab program as a whole, in collaborating with us to evaluate bavituximab in combination with other novel immunotherapies, in collaborating with us on new areas, and in our contract manufacturing services. With the Phase III study now underway, our main interest in partnering for the bavituximab program would be to allow us to be more aggressive in advancing new clinical indications, namely moving new indications in the later-stage development in areas such as Breast & Liver cancer. And we look forward to updating you as partnerships are brought to fruition over the coming year.

After today, 46 calendar days remain until the above statement is one year old. Keep in mind, the above is a prepared statement.